Search results

Selected filters:

Valuation
Analysis

Article type

Topic

Sector

Regions

Year

537 results found for your search

Sort options
13 September 2019

The world's most valuable patent revealed - and it's not owned by a pharma giant or a BigTech titan

New index attempts to score grants by family, according to where they’re filed and to what extent they're cited. We list the top 10 its methodology produces

10 September 2019

Chinese investors dig into IP portfolios

Research reports in China increasingly highlight companies whose claims to innovation may not jibe with their patent portfolios

02 September 2019

Sinda may test the market for Chinese IP firm takeovers

A report says the patent filing powerhouse is attracting private equity interest at a possible valuation of around $300 million

30 August 2019

Amgen’s $13.4 billion Otezla purchase shows, once more, the direct financial value of IP in the life sciences space

The Californian company cites US patent protection until 2028 as a key driver of the psoriasis drug acquisition, but antitrust concerns remain

27 August 2019

Armed and dangerous - how patents help Unicorns to fight back

Tech-rich start-ups that do not develop portfolios are vulnerable to attack - as recent Houlihan Lokey analysis of pre-IPO software businesses' IP positions revealed 

26 August 2019

IPO documents detail a Chinese AI leader's IP portfolio

Megvii's patent portfolio is heavily China-focused, but analysis suggests it could contain a gem

26 August 2019

Three key IP takeaways from Bayer's $7.6 billion sale of its animal health unit

The German company's divestiture to Elanco is the latest example of a pharma giant fleeing non-core business areas - and it is unlikely to be the last

09 August 2019

NASA’s portfolio is the definition of lean and mean

The iconic agency – which celebrated the 50th anniversary of putting the first man on the moon last month - is highly selective with the innovations it patents and constantly reviews holdings to eliminate deadweight

06 August 2019

Record-breaking pharma M&A value disguises plummeting deal-making activity

Abundant biotech funding seems to be empowering small- and medium-sized IP rights holders and driving down acquisition and licensing volume

05 August 2019

China seeks to boost IP lending

Companies staked patents and trademarks to borrow $8.5 billion in the first half of 2019. CNIPA and China’s banking regulator want that figure to increase as SMEs face a credit squeeze

01 August 2019

Expect Pfizer set to focus on more oncology opportunities following off-patent drug purge

After $12 billion Upjohn deal with Mylan, CEO Bourla says company is on the hunt for early- and mid-stage cancer assets

29 July 2019

South Korean court asked to sell off IP portfolio seized from Mitsubishi Heavy Industries

Lawyers have requested that patents and trademarks seized from the Japanese company in March be put on the market after it failed to comply with an order to pay compensation to Korean citizens subjected to forced labour during WW2

19 July 2019

Alphabet is trimming down its portfolio - but only after sustained growth  

The tech giant saw a steep drop in the number of US patents granted in 2018 after having spent years building its portfolio organically and through strategic acquisitions

16 July 2019

Gilead’s unique $5.1 billion licensing deal shows the range of IP monetisation options open to biotech sector

New boss explains that the Big Pharma company will seek out “diverse and creative” asset partnerships – rather than large acquisitions – to boost its pipeline

08 July 2019

Bankrupt mobile firm's patents could hit the market soon

It wouldn't be the summer’s biggest auction, but Gionee’s China-heavy smartphone patent portfolio could draw interest from Chinese operating companies and NPEs focused on the market